RE: Accustem Future21 Oct 2020 16:19
Hi Nelsonthedog, I agree with a lot of your post, however, step 1 is to get the Demerger done (i.e. get to 1st November). Once that’s done, StemPrinter is “packaged up” and ready for someone to walk away with if they pay the asking price (whatever that is).
Don’t forget there is the “formality” of a further court hearing to get through. No point being presumptuous. Imo, “day 1” as you put it, starts on 1st November.
I also suspect that IF negotiations are under way (and we of course do not know if they are) that our BoD know what they have in StemPrinter (45% better than the best with tests and evidence to back that up) so they will be playing hard ball.
As I mentioned earlier, the gap between Demerger and listing in U.K. and further gap to “potentially” Listing on Nasdaq allows enough time to continue any negotiations, with the Nasdaq listing providing the funding if we want/need to go it alone. The BoD have also said Q1 for Roll Out into hospital (s) in Italy first, so they will have evidence also to support that intention.
There are lots of ifs and buts, however, I don’t think the BoD will be left wanting when it comes to negotiations in this respect.
GL